-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Net, April 29, 487.
5 million yuan, a well-known pharmaceutical company was acquired
5 million yuan, a well-known pharmaceutical company was acquired
Well-known pharmaceutical company was acquired
Huadong Medicine announced the acquisition of a 75% stake in Zhejiang Daoer Biotechnology Co.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
After the completion of this transaction, Doer Bio will become the company's holding grandson company.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
The aforesaid equity purchase agreement will take effect from the day when the parties to the cooperation signed (April 26).
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
The announcement emphasized that the acquisition does not involve personnel placement, land lease, creditor's rights and debt restructuring, etc.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
The annual report shows that Huadong Medicine's 2020 revenue was 33.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
The announcement stated that, combined with the financial status of the company and East China, this transaction will not have a significant impact on the company's current and future operating indicators and cash flow.
Layout innovative drug research and development
According to public information, Daoer Biotechnology was established on April 1, 2014.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
Among them, one product for the treatment of gastric cancer and two products for the treatment of metabolic diseases such as type II diabetes and NASH have basically completed the pre-clinical research work and plan to submit clinical trial applications in 2021.
Prior to this, Doer Bio had completed nearly 100 million yuan in A+ round of financing.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
On April 19th, Huadong Medicine reached a cooperation with Nuo Ling Bio, a new generation of antibody coupling technology with independent intellectual property rights, and held 10.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
Last year, the two core products of Huadong Pharmaceutical were affected by policies such as mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
At present, Huadong Medicine's 2020 performance has exposed the weakness of product revenue.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
Broad prospects for development
In recent years, capital and policies have begun to bring more changes to innovative drugs.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
In 2019, the General Office of the Provincial Party Committee and the General Office of the Provincial Government issued a notice to issue the " Implementation Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices " to guide pharmaceutical companies to increase R&D investment and accelerate the review, approval and review of innovative drugs.
The pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
The pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
After the domestic pharmaceutical company Hengrui Pharmaceuticals transforms and develops innovative drugs, in 2020, a total of 82 innovative drug clinical approvals have been obtained, of which 6 major research projects have entered the two-thirds clinical stage.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
Coincidentally, Fosun Pharma, Junshi Biotech and other companies have achieved outstanding results in the field of innovative drugs.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
According to NMPA statistics, in 2019, the number of new drugs approved in China reached 48, and the 48 approved new drugs were declared by domestic companies in 13 varieties.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
Bio-innovative drugs have become a battleground for pharmaceutical companies, and domestic bio-pharmaceutical companies continue to invest in the research and development of bio-innovative drugs.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
Pharmaceutical Net, April 29, 487.
5 million yuan, a well-known pharmaceutical company was acquired
5 million yuan, a well-known pharmaceutical company was acquired
Well-known pharmaceutical company was acquired
Huadong Medicine announced the acquisition of a 75% stake in Zhejiang Daoer Biotechnology Co.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
After the completion of this transaction, Doer Bio will become the company's holding grandson company.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
The aforesaid equity purchase agreement will take effect from the day when the parties to the cooperation signed (April 26).
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
The announcement emphasized that the acquisition does not involve personnel placement, land lease, creditor's rights and debt restructuring, etc.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
The annual report shows that Huadong Medicine's 2020 revenue was 33.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
The announcement stated that, combined with the financial status of the company and East China, this transaction will not have a significant impact on the company's current and future operating indicators and cash flow.
Layout innovative drug research and development
According to public information, Daoer Biotechnology was established on April 1, 2014.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
Among them, one product for the treatment of gastric cancer and two products for the treatment of metabolic diseases such as type II diabetes and NASH have basically completed the pre-clinical research work and plan to submit clinical trial applications in 2021.
Prior to this, Doer Bio had completed nearly 100 million yuan in A+ round of financing.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
On April 19th, Huadong Medicine reached a cooperation with Nuo Ling Bio, a new generation of antibody coupling technology with independent intellectual property rights, and held 10.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
Last year, the two core products of Huadong Pharmaceutical were affected by policies such as mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
At present, Huadong Medicine's 2020 performance has exposed the weakness of product revenue.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
Broad prospects for development
In recent years, capital and policies have begun to bring more changes to innovative drugs.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
In 2019, the General Office of the Provincial Party Committee and the General Office of the Provincial Government issued a notice to issue the " Implementation Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices " to guide pharmaceutical companies to increase R&D investment and accelerate the review, approval and review of innovative drugs.
The pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
The pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
After the domestic pharmaceutical company Hengrui Pharmaceuticals transforms and develops innovative drugs, in 2020, a total of 82 innovative drug clinical approvals have been obtained, of which 6 major research projects have entered the two-thirds clinical stage.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
Coincidentally, Fosun Pharma, Junshi Biotech and other companies have achieved outstanding results in the field of innovative drugs.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
According to NMPA statistics, in 2019, the number of new drugs approved in China reached 48, and the 48 approved new drugs were declared by domestic companies in 13 varieties.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
Bio-innovative drugs have become a battleground for pharmaceutical companies, and domestic bio-pharmaceutical companies continue to invest in the research and development of bio-innovative drugs.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
Pharmaceutical Net, April 29, 487.
5 million yuan, a well-known pharmaceutical company was acquired
5 million yuan, a well-known pharmaceutical company was acquired
Well-known pharmaceutical company was acquired
Well-known pharmaceutical company was acquired Huadong Medicine announced the acquisition of a 75% stake in Zhejiang Daoer Biotechnology Co.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
, Ltd.
for RMB 487.
5 million and became its controlling shareholder.
After the completion of the transaction, Huadong Medicine became its largest shareholder.
After the completion of this transaction, Doer Bio will become the company's holding grandson company.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
If the target company fails to meet the expected target in its future operations after the completion of this acquisition, there is a risk of impairment of the relevant goodwill, which will adversely affect the company's future operating results.
The aforesaid equity purchase agreement will take effect from the day when the parties to the cooperation signed (April 26).
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
After the completion of this transaction, Doyle Biotech established a new board of directors, which consists of 5 directors, of which Sino-US East China has the right to appoint 4 directors.
The announcement emphasized that the acquisition does not involve personnel placement, land lease, creditor's rights and debt restructuring, etc.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
After the completion of this acquisition, the company and Doer Biotech will not have associated transactions and competition in the same industry.
The annual report shows that Huadong Medicine's 2020 revenue was 33.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
68 billion yuan, a year-on-year decrease of 4.
97%; attributable net profit was 2.
82 billion yuan, a year-on-year increase of 0.
24%.
The announcement stated that, combined with the financial status of the company and East China, this transaction will not have a significant impact on the company's current and future operating indicators and cash flow.
Layout innovative drug research and development
Layout innovative drug research and development According to public information, Daoer Biotechnology was established on April 1, 2014.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
It is a research and development enterprise specializing in the development of innovative biopharmaceuticals with multiple independent intellectual property rights and a unique protein engineering technology platform.
Doyle Bio focuses on the development of multi-domain-based multi-specific innovative fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of tumors, metabolism, and ophthalmology.
Among them, one product for the treatment of gastric cancer and two products for the treatment of metabolic diseases such as type II diabetes and NASH have basically completed the pre-clinical research work and plan to submit clinical trial applications in 2021.
Prior to this, Doer Bio had completed nearly 100 million yuan in A+ round of financing.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
The raised funds will be used to promote the clinical application of the company's three first-class innovative drugs, as well as follow-up pipeline R&D and preclinical research.
On April 19th, Huadong Medicine reached a cooperation with Nuo Ling Bio, a new generation of antibody coupling technology with independent intellectual property rights, and held 10.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
4478% equity of Nuo Ling Bio with a total of 35 million yuan.
In this week or so, Huadong Biotechnology has completed two transactions one after another.
Last year, the two core products of Huadong Pharmaceutical were affected by policies such as mass pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
pharmnet. com.
cn/news/yyzb/" target="_blank">procurement and medical insurance negotiations.
In the second round of centralized procurement in January 2020, Bayer Acarbose offered 0.
18 yuan/piece, directly squeezing out the core product of East China Medicine, Carboping, and then at the end of 2020, the company’s Sino-US East China unit exceeded 100 million orders.
Pinbailing capsules were included in the new version of the medical insurance catalog, and the price dropped sharply.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
At present, Huadong Medicine's 2020 performance has exposed the weakness of product revenue.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
With the change of policy, future revenue may be further affected.
According to the announcement, Dow Biotech focuses on the research and development of drugs in the field of tumor and metabolism, which is highly compatible with the areas of Huadong Pharmaceutical Company's research and development focus.
It can be seen that the cooperation between Huadong Medicine and Nuo Ling Biological and Doer Biological will undoubtedly promote the company to achieve further breakthroughs.
Broad prospects for development
Broad prospects for development In recent years, capital and policies have begun to bring more changes to innovative drugs.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
With the steady progress of centralized procurement, China Pharmaceuticals has entered an innovation-driven development track, and more and more companies have begun to deploy innovative drug R&D and production.
In 2019, the General Office of the Provincial Party Committee and the General Office of the Provincial Government issued a notice to issue the " Implementation Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices " to guide pharmaceutical companies to increase R&D investment and accelerate the review, approval and review of innovative drugs.
The pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
Drugs medical equipment medicines medicines Medical Devices medical equipment pharmaceutical companies Pharmaceutical pharmaceutical business enterprisesThe pace of listing has promoted the rapid development of the innovative drug industry from top to bottom.
After the domestic pharmaceutical company Hengrui Pharmaceuticals transforms and develops innovative drugs, in 2020, a total of 82 innovative drug clinical approvals have been obtained, of which 6 major research projects have entered the two-thirds clinical stage.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
According to IQVIA data, Hengrui's PD-1 sales exceed 2 billion.
Coincidentally, Fosun Pharma, Junshi Biotech and other companies have achieved outstanding results in the field of innovative drugs.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
For example, Henlius's innovative monoclonal antibodies HLX06, HLX08, HLX09 and HLX10 are leading domestic innovative monoclonal antibody projects, and Fosun Pharma’s monoclonal antibody business will reach RMB 5.
028 billion in 2018.
According to IQVIA data, Cinda Bio-Sintilimab achieved a cumulative sales revenue of approximately 900 million yuan in the first half of the year; Junshi’s sales revenue of triprolimab from January to September 2020 was 689 million yuan.
According to NMPA statistics, in 2019, the number of new drugs approved in China reached 48, and the 48 approved new drugs were declared by domestic companies in 13 varieties.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
It can be seen that the enthusiasm of domestic pharmaceutical companies in the development of new drugs has become higher and higher.
Bio-innovative drugs have become a battleground for pharmaceutical companies, and domestic bio-pharmaceutical companies continue to invest in the research and development of bio-innovative drugs.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
In the future, more pharmaceutical companies will develop new products to join the market competition, and pharmaceutical companies must accelerate the innovation and transformation of layout in order to gain a competitive advantage.
